Living tissue-engineered heart valves (TEHV) would be a major benefit for children who require a replacement with the capacity for growth and biological integration. A persistent challenge for TEHV is accessible human cell source(s) that can mimic native valve cell phenotypes and matrix remodeling characteristics that are essential for long-term function. Mesenchymal stem cells derived from bone marrow (BMMSC) or adipose tissue (ADMSC) are intriguing cell sources for TEHV, but they have not been compared with pediatric human aortic valve interstitial cells (pHAVIC) in relevant 3D environments. In this study, we compared the spontaneous and induced multipotency of ADMSC and BMMSC with that of pHAVIC using different induction media within three-dimensional (3D) bioactive hybrid hydrogels with material modulus comparable to that of aortic heart valve leaflets. pHAVIC possessed some multi-lineage differentiation capacity in response to induction media, but limited to the earliest stages and much less potent than either ADMSC or BMMSC. ADMSC expressed cell phenotype markers more similar to pHAVIC when conditioned in basic fibroblast growth factor (bFGF) containing HAVIC growth medium, while BMMSC generally expressed similar extracellular matrix remodeling characteristics to pHAVIC. Finally, we covalently attached bFGF to PEG monoacrylate linkers and further covalently immobilized in the 3D hybrid hydrogels. Immobilized bFGF upregulated vimentin expression and promoted the fibroblastic differentiation of pHAVIC, ADMSC, and BMMSC. These findings suggest that stem cells retain a heightened capacity for osteogenic differentiation in 3D culture, but can be shifted toward fibroblast differentiation through matrix tethering of bFGF. Such a strategy is likely important for utilizing stem cell sources in heart valve tissue engineering applications.
Get full access to this article
View all access options for this article.
References
1.
NkomoV.T., GardinJ.M., SkeltonT.N., GottdienerJ.S., ScottC.G., and Enriquez-SaranoM.Burden of valvular heart diseases: a population-based study. Lancet, 368, 1005, 2006.
2.
GandagliaA., BagnoA., NasoF., SpinaM., and GerosaG.Cells, scaffolds and bioreactors for tissue-engineered heart valves: a journey from basic concepts to contemporary developmental innovations. Eur J Cardio-Thorac Surg, 39, 523, 2011.
3.
CheungA., WebbJG., BarbantiM., FreemanM., BinderR.K., ThompsonC., et al.5-Year experience with transcatheter transapical mitral valve-in-valve implantation for bioprosthetic valve dysfunction. J Am Coll Cardiol, 61, 1759, 2013.
4.
SacksM.S., SchoenF.J., and MayerJ.E.J.Bioengineering challenges for heart valve tissue engineering. Annu Rev Biomed Eng, 11, 289, 2009.
5.
ButcherJ.T., MahlerG.J., and HockadayL.A.Aortic valve disease and treatment: the need for naturally engineered solutions. Adv Drug Deliv Rev, 63, 242, 2011.
6.
ShinokaT., BreuerC.K., TanelR.E., ZundG., MiuraT., MaP.X., et al.Tissue engineering heart valves: valve leaflet replacement study in a lamb model. Ann Thorac Cardiovasc Surg, 60, S513, 1995.
7.
SteinhoffG., StockU., KarimN., MertschingH., TimkeA., MelissR.R., et al.Tissue engineering of pulmonary heart valves on allogenic acellular matrix conduits - in vivo restoration of valve tissue. Circulation, 102, 50, 2000.
8.
FlanaganT.C., SachwehJ.S., FreseJ., SchnoringH., GronlohN., KochS., et al.In vivo remodeling and structural characterization of fibrin-based tissue-engineered heart valves in the adult sheep model. Tissue Eng Part A, 15, 2965, 2009.
9.
SchmidtD., StockU.A., and HoerstrupS.P.Tissue engineering of heart valves using decellularized xenogeneic or polymeric starter matrices. Trans R Soc B-Biol Sci, 362, 1505, 2007.
10.
BaderA., SchillingT., TeebkenO.E., BrandesG., HerdenT., SteinhoffG., et al.Tissue engineering of heart valves - human endothelial cell seeding of detergent acellularized porcine valves. Eur J Cardio-Thorac Surg, 14, 279, 1998.
11.
Hoffman-KimD., MaishM.S., KruegerP.M., LukoffH., BertA., HongT., et al.Comparison of three myofibroblast cell sources for the tissue engineering of cardiac valves. Tissue Eng, 11, 288, 2005.
12.
WeberB., EmmertM.Y., and HoerstrupS.P.Stem cells for heart valve regeneration. Swiss Med Wkly, 142, w13622, 2012.
13.
RippelR.A., GhanbariH., and SeifalianA.M.Tissue-engineered heart valve: future of cardiac surgery. World J Surg, 36, 1581, 2012.
14.
WeberB., EmmertM.Y., BehrL., SchoenauerR., BrokoppC., DrogemullerC., et al.Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal circulation. Biomaterials, 33, 4031, 2012.
15.
PerryT.E., KaushalS., SutherlandF.W.H., GuleserianK.J., BischoffJ., SacksM., et al.Bone marrow as a cell source for tissue engineering heart valves. Ann Thorac Surg, 75, 761, 2003.
16.
DijkmanP.E., Driessen-MolA., FreseL., HoerstrupS.P., and BaaijensF.P.T.Decellularized homologous tissue-engineered heart valves as off-the-shelf alternatives to xeno- and homografts. Biomaterials, 33, 4545, 2012.
17.
SyedainZ.H., BradeeA.R., KrenS., TaylorD.A., and TranquilloR.T.Decellularized tissue-engineered heart valve leaflets with recellularization potential. Tissue Eng Part A, 19, 759, 2013.
18.
WeberB., SchermanJ., EmmertM.Y., GruenenfelderJ., VerbeekR., BracherM., et al.Injectable living marrow stromal cell-based autologous tissue engineered heart valves: first experiences with a one-step intervention in primates. Eur Heart J, Suppl. 32, 2830, 2011.
19.
ColazzoF., SarathchandraP., SmolenskiR.T., ChesterA.H., TsengY.T., CzernuszkaJ.T., et al.Extracellular matrix production by adipose-derived stem cells: implications for heart valve tissue engineering. Biomaterials, 32, 119, 2011.
20.
AikawaE., WhittakerP., FarberM., MendelsonK., PaderaR.F., AikawaM., et al.Human semilunar cardiac valve remodeling by activated cells from fetus to adult - Implications for postnatal adaptation, pathology, and tissue engineering. Circulation, 113, 1344, 2006.
21.
YipC.Y.Y., and SimmonsC.A.The aortic valve microenvironment and its role in calcific aortic valve disease. Cardiovasc Pathol, 20, 177, 2011.
22.
StephensE.H., ChuC.K., and Grande-AllenK.J.Valve proteoglycan content and glycosaminoglycan fine structure are unique to microstructure, mechanical load and age: Relevance to an age-specific tissue-engineered heart valve. Acta Biomater, 4, 1148, 2008.
23.
LatifN., SarathchandraP., ThomasP.S.A., BattenP., ChesterA.H., TaylorP.M., et al.Characterization of structural and signaling molecules by human valve interstitial cells and comparison to human mesenchymal stem cells. J Heart Valve Dis, 16, 56, 2007.
24.
ButcherJ.T., and NeremR.M.Porcine aortic valve interstitial cells in three-dimensional culture: Comparison of phenotype with aortic smooth muscle cells. J Heart Valve Dis, 13, 478, 2004.
25.
ChenJ.H., YipC.Y.Y., SoneE.D., and SimmonsC.A.Identification and characterization of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential. Am J Pathol, 174, 1109, 2009.
26.
WirrigE.E., HintonR.B., and YutzeyK.E.Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. J Mol Cell Cardiol, 50, 561, 2011.
27.
DuanB., HockadayL.A., KapetanovicE., KangK.H., and ButcherJ.T.Stiffness and adhesivity control aortic valve interstitial cell behavior within hyaluronic acid based hydrogels. Acta Biomater, 9, 7640, 2013.
28.
DuanB., KapetanovicE., HockadayL.A., and ButcherJ.T.Three-dimensional printed trileaflet valve conduits using biological hydrogels and human valve interstitial cells. Acta Biomater, 10, 1836, 2014.
29.
MahlerG.J., FarrarE.J., and ButcherJ.T.Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells. Arterioscler Thromb Vasc Biol, 33, 121, 2013.
30.
FerdousZ., JoH., and NeremR.M.Strain magnitude-dependent calcific marker expression in valvular and vascular cells. Cells Tissues Organs, 197, 372, 2013.
31.
FerdousZ., JoH., and NeremR.M.Differences in valvular and vascular cell responses to strain in osteogenic media. Biomaterials, 32, 2885, 2011.
32.
McBeathR., PironeD.M., NelsonC.M., BhadrirajuK., and ChenC.S.Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell, 6, 483, 2004.
33.
KernS., EichlerH., StoeveJ., KluterH., and BiebackK.Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells, 24, 1294, 2006.
34.
ChiangH.S., HsiehC.H., LinY.H., LinS.M., Tsai-WuJ.J., and JiangC.C.Differences between chondrocytes and bone marrow-derived chondrogenic cells. Tissue Eng Part A, 17, 2919, 2011.
35.
DuanB., HockadayL.A., KangK.H., and ButcherJ.T.3D bioprinting of heterogeneous aortic valve conduits with alginate/gelatin hydrogels. J Biomed Mater Res Part A, 101A, 1255, 2013.
36.
RichardsJ., El-HamamsyI., ChenS., SarangZ., SarathchandraP., YacoubM.H., et al.Side-specific endothelial-dependent regulation of aortic valve calcification interplay of hemodynamics and nitric oxide signaling. Am J Pathol, 182, 1922, 2013.
37.
EdwardsC.A., and ObrienW.D.Modified assay for determination of hydroxyproline in a tissue hydrolyzate. Clin Chim Acta, 104, 161, 1980.
38.
JinR., TeixeiraL.S.M., DijkstraP.J., van BlitterswijkC.A., KarperienM., and FeijenJ.Enzymatically-crosslinked injectable hydrogels based on biomimetic dextran-hyaluronic acid conjugates for cartilage tissue engineering. Biomaterials, 31, 3103, 2010.
39.
ButcherJ.T., NorrisR.A., HoffmanS., MjaatvedtC.H., and MarkwaldR.R.Periostin promotes atrioventricular mesenchyme matrix invasion and remodeling mediated by integrin signaling through Rho/PI 3-kinase. Dev Biol, 302, 256, 2007.
40.
RabkinE., AikawaM., StoneJ.R., FukumotoY., LibbyP., and SchoenF.J.Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation, 104, 2525, 2001.
41.
QuinlanA.M.T., and BilliarK.L.Investigating the role of substrate stiffness in the persistence of valvular interstitial cell activation. J Biomed Mater Res Part A, 100A, 2474, 2012.
42.
Kruzynska-FrejtagA., MachnickiM., RogersR., MarkwaldR.R., and ConwayS.J.Periostin (an osteoblast-specific factor) is expressed within the embryonic mouse heart during valve formation. Mech Dev, 103, 183, 2001.
43.
SniderP., HintonR.B., Moreno-RodriguezR.A., WangJ., RogersR., LindsleyA., et al.Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ Res, 102, 752, 2008.
44.
NorrisR.A., Moreno-RodriguezR.A., SugiY., HoffmanS., AmosJ., HartM.M., et al.Periostin regulates atrioventricular valve maturation. Dev Biol, 316, 200, 2008.
45.
ZeisbergE.M., TarnavskiO., ZeisbergM., DorfmanA.L., McMullenJ.R., GustafssonE., et al.Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med, 13, 952, 2007.
46.
TaylorP.M., AllenS.P., and YacoubM.H.Phenotypic and functional characterization of interstitial cells from human heart valves, pericardium and skin. J Heart Valve Dis, 9, 150, 2000.
47.
HalfonS., AbramovN., GrinblatB., and GinisI.Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev, 20, 53, 2011.
48.
RiceJ.J., MartinoM.M., De LaporteL., TortelliF., BriquezP.S., and HubbellJ.A.Engineering the regenerative microenvironment with biomaterials. Adv Healthc Mater, 2, 57, 2013.
DeLongS.A., MoonJ.J., and WestJ.L.Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. Biomaterials, 26, 3227, 2005.
52.
ZhaoR.G., SiderK.L., and SimmonsC.A.Measurement of layer-specific mechanical properties in multilayered biomaterials by micropipette aspiration. Acta Biomater, 7, 1220, 2011.
53.
TaylorP.A., BattenP., BrandN.J., ThomasP.S., and YacoubM.H.The cardiac valve interstitial cell. Int J Biochem Cell Biol, 35, 113, 2003.
54.
ChesterA.H., and TaylorP.M.Molecular and functional characteristics of heart-valve interstitial cells. Philosophical Trans R Soc B-Biol Sci, 362, 1437, 2007.
55.
DiGirolamoC.M., StokesD., ColterD., PhinneyD.G., ClassR., and ProckopD.J.Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol, 107, 275, 1999.
56.
LiZ.L., LiuC.X., XieZ.H., SongP.Y., ZhaoR.C.H., GuoL., et al.Epigenetic dysregulation in mesenchymal stem cell aging and spontaneous differentiation. Plos One, 6, e20526, 2011.
57.
WallM.E., BernackiS.H., and LoboaE.G.Effects of serial passaging on the adipogenic and osteogenic differentiation potential of adipose-derived human mesenchymal stem cells. Tissue Eng, 13, 1291, 2007.
58.
TsengP.C., YoungT.H., WangT.M., PengH.W., HouS.M., and YenM.L.Spontaneous osteogenesis of MSCs cultured on 3D microcarriers through alteration of cytoskeletal tension. Biomaterials, 33, 556, 2012.
PoggioP., SaingerR., BranchettiE., GrauJ.B., LaiE.K., GormanR.C., et al.Noggin attenuates the osteogenic activation of human valve interstitial cells in aortic valve sclerosis. Cardiovasc Res, 98, 402, 2013.
61.
FisherC.I., ChenJ., and MerrymanW.D.Calcific nodule morphogenesis by heart valve interstitial cells is strain dependent. Biomech Model Mechanobiol, 12, 5, 2013.
62.
RodriguezK.J., PiechuraL.M., and MastersK.S.Regulation of valvular interstitial cell phenotype and function by hyaluronic acid in 2-D and 3-D culture environments. Matrix Biol, 30, 70, 2011.
63.
HanL., and GotliebA.I.Fibroblast growth factor-2 promotes in vitro mitral valve interstitial cell repair through transforming growth factor-beta/smad signaling. Am J Pathol, 178, 119, 2011.
64.
HanL., and GotliebA.I.Fibroblast growth factor-2 promotes in vitro heart valve interstitial cell repair through the Akt1 pathway. Cardiovasc Pathol, 21, 382, 2012.
65.
GotliebA.I., RosenthalA., and KazemianP.Fibroblast growth factor 2 regulation of mitral valve interstitial cell repair in vitro. J Thorac Cardiovasc Surg, 124, 591, 2002.
66.
Sewell-LoftinM.K., ChunY.W., KhademhosseiniA., and MerrymanW.D.EMT-inducing biomaterials for heart valve engineering: Taking cues from developmental biology. J Cardiovasc Transl Res, 4, 658, 2011.
67.
ChenH.C., ZhuY.T., ChenS.Y., and TsengS.C.G.Wnt signaling induces epithelial-mesenchymal transition with proliferation in ARPE-19 cells upon loss of contact inhibition. Lab Invest, 92, 676, 2012.
68.
NarineK., De WeverO., Van ValckenborghD., FrancoisK., BrackeM., DesmetS., et al.Growth factor modulation of fibroblast proliferation, differentiation, and invasion: implications for tissue valve engineering. Tissue Eng, 12, 2707, 2006.
69.
SomersP., CornelissenR., ThierensH., and van NootenG.An optimized growth factor cocktail for ovine mesenchymal stem cells. Growth Factors, 30, 37, 2012.
70.
SongT., WangW.J., XuJ., ZhaoD., DongQ., LiL., et al.Fibroblast growth factor 2 inhibits bone morphogenetic protein 9-induced osteogenic differentiation of mesenchymal stem cells by repressing Smads signaling and subsequently reducing Smads dependent up-regulation of ALK1 and ALK2. Int J Biochem Cell Biol, 45, 1639, 2013.
71.
BiverE., SoubrierA.S., ThouvereyC., CortetB., BrouxO., CaverzasioJ., et al.Fibroblast growth factor 2 inhibits up-regulation of bone morphogenic proteins and their receptors during osteoblastic differentiation of human mesenchymal stem cells. Biochem Biophys Res Commun, 427, 737, 2012.
72.
SohierJ., CarubelliI., SarathchandraP., LatifN., ChesterA.H., and YacoubM.H.The potential of anisotropic matrices as substrate for heart valve engineering. Biomaterials, 35, 1833, 2014.
73.
TedderM.E., SimionescuA., ChenJ., LiaoJ., and SimionescuD.T.Assembly and testing of stem cell-seeded layered collagen constructs for heart valve tissue engineering. Tissue Eng Part A, 17, 25, 2011.
74.
SieradL.N., SimionescuA., AlbersC., ChenJ., MaivelettJ., TedderM.E., et al., Design and testing of a pulsatile conditioning system for dynamic endothelialization of polyphenol-stabilized tissue engineered heart valves. Cardiovasc Eng Tech, 1, 138, 2010.
75.
Leslie-BarbickJ.E., ShenC., ChenC., and WestJ.L.Micron-scale spatially patterned, covalently immobilized vascular endothelial growth factor on hydrogels accelerates endothelial tubulogenesis and increases cellular angiogenic responses. Tissue Eng Part A, 17, 221, 2011.
76.
AltE., YanY.S., GehmertS., SongY.H., AltmanA., GehmertS., et al.Fibroblasts share mesenchymal phenotypes with stem cells, but lack their differentiation and colony-forming potential. Biol Cell, 103, 197, 2011.
77.
HintonR.B., and YutzeyK.E.Heart valve structure and function in development and disease. Annu Rev Physiol, 73, 29, 2011.
78.
SchoenF.J.Mechanisms of fuction and disease of natural and replacement heart valves. Annu Rev Pathol-Mech Dis, 7, 161, 2012.
79.
ChenJ.H., and SimmonsC.A.Cell-matrix interactions in the pathobiology of calcific aortic valve disease critical roles for matricellular, matricrine, and matrix mechanics cues. Circ Res, 108, 1510, 2011.
80.
HamiltonA.M., BoughnerD.R., DrangovaM., and RogersK.A.Statin treatment of hypercholesterolemic-induced aortic valve sclerosis. Cardiovasc Pathol, 20, 84, 2011.
81.
StephensE.H., SaltarrelliJ.G., BaggettL.S., NandiI., KuoJ.J., DavisA.R., et al.Differential proteoglycan and hyaluronan distribution in calcified aortic valves. Cardiovasc Pathol, 20, 334, 2011.
82.
BaileyM.T., PillarisettiS., XiaoH., and VyavahareN.R.Role of elastin in pathologic calcification of xenograft heart valves. J Biomed Mater Res Part A, 66A, 93, 2003.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
